Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tissue Regenix has announced that its partner, NHS Blood and Transplant (NHSBT), has initiated a pilot study to evaluate the use of decellularised human donor skin grafts (dCELL Human Dermis) in the treatment of chronic, non-healing wounds, utilising Tissue Regenix's proprietary dCELL technology.
Subscribe to our email newsletter
The pilot study will enroll 20 patients with existing chronic wounds, who will be monitored over a 42-day period in order to evaluate the effectiveness of dCELL Human Dermis in improving the closure of chronic wounds.
The pilot study is designed to assess the responsiveness of chronic wounds to determine the size of a larger, multi-centred study.
Patients will be monitored for up to six months following completion of the pilot study.
The study will be conducted at the University Hospital of South Manchester (UHSM), and the initial pilot study will be largely funded by the NHSBT.